Analyst Ratings For Mirum Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analyst ratings for Mirum Pharmaceuticals (NASDAQ:MIRM) show a mix of bullish and somewhat bullish perspectives with no bearish views in the last three months. The average 12-month price target is $52.6, slightly down from $53.29. Mirum Pharmaceuticals, a biopharmaceutical company, has shown significant revenue growth and strong financial performance, with a focus on developing treatments for rare diseases. Analysts' actions range from maintaining to raising and lowering their price targets and ratings, reflecting their response to the company's performance and market conditions.
May 09, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals has received a mix of bullish and somewhat bullish ratings from analysts, with an updated average 12-month price target of $52.6. The company's significant revenue growth and strong financial indicators, such as ROE and ROA, highlight its robust performance and potential for future growth.
The positive analyst ratings and the slight adjustment in the price target reflect confidence in Mirum Pharmaceuticals' ongoing and future performance. The company's focus on rare diseases and its strong financial metrics, including a notable revenue growth rate and impressive ROE and ROA, support a positive outlook. The mix of ratings and the adjustments in price targets suggest analysts are reacting to both the company's recent achievements and market conditions, which could influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100